Conclusion+and+Relation+to+Medical+Practice

=Conclusions and Relation to Medical Practice: =

Conclusions:
This discovery of 27HC is a big jump in ER positive breast cancer research as it works with an alternative to estrogen limitation for the treatment of breast cancer. For all of those patients who come in with resistance to estrogen drugs or who’s cancer does not respond to estrogen therapy now have a path of treatment available. This research is very important for postmenopausal women, who generally have much more 27HC in their system due to lower levels of estrogen. This discovery of 27HC’s agonist ER receptor activity really broadens the treatment options in women who previously had fewer options for treatment of ER positive breast cancer. Another demographic of patients that will now receive more treatment options are those with hypercholesterolemia, disease often associated with obesity. With these patients there tends to be elevated levels of cholesterol and 27HC in the bloodstream and cells. This would greatly promote the chance of ER positive breast cancer proliferation as the cancer cells have many more promoters available. Finally, when it comes to tamoxifen treatment, it has been discovered that tamoxifen can actually promote abundance of 27HC and, in a subset of ER positive breast cancer patients, ends up promoting the growth of the cancer. This is an analysis that can now be done to prevent any unwanted proliferation of the tumor. The avenues of treatment that can be achieved due to the discovery of 27HC’s estrogen agonist behavior are incredible and will lead to better, more personalized treatment of certain demographics of patients. The following analysis will present ideas for treatment based on 27HC.

CYP7B1 treatment for ER positive breast cancer:

As stated in the section labeled //CYP7B1 catabolism of 27HC//, women who showed higher levels of CYP7B1 in their breast cells had much better outcomes from their breast cancer treatment (Nelson). These results are very promising and may lead researchers to come up with ways to further stimulate higher CYP7B1 in patients to help increase the number of positive outcomes from ER positive breast cancer. Although this may not cure the cancer, it will significantly lower the levels of 27HC in the cells, greatly decreasing cell proliferation. The other benefit is the fact that CYP7B1 is a natural enzyme in cholesterol metabolism and would not be a new addition to the body chemistry. Hopefully this would cause for less side effects and be a more comfortable treatment. Inhibitors of 27HC and their potential treatment uses:

 On our page labeled //Inhibitors of 27HC//, we profiled to potential inhibitors that would limit the binding of 27HC to the estrogen receptors. ICI 182,780, also known as Fulvestrant, is an estrogen receptor antagonist. By competitively binding the estrogen receptor, it limits the binding of any ER agonists, therefore limiting cell proliferation. Although it was not known previously, ICI 182,780 binds the ER receptor better than 27HC, therefore limiting its agonist activity (Nelson). This would be a good treatment for any type of ER positive breast cancer as it works on the receptor and not the agonist. Also, when it is paired with CYP7B1, the inhibition results are amplified. This cocktail would attack from the receptor and 27HC level and greatly limit cell proliferation. The new inhibitor of 27HC is GW3965, which works on the liver-x-receptor. This receptor is very important in cholesterol metabolism, working to excrete cholesterol and its metabolites from the cell. Although I call it an inhibitor of 27HC, it is actually more of a promoter of the liver-x-receptor, which in turn inhibits the expression of 27HC (Zhao). This molecule can be used to limit the amount of cholesterol in the body, helping to limit 27HC levels and therefore limit cell proliferation. Studies in mice show promising results, that this LXR promoter is very effective in stopping the promoting effects of 27HC. This would be a new viable treatment option for women who meet the correct criteria for 27HC breast cancer treatment.

Tamoxifen
For more information of Tamoxifen resistance and 27HC's promotion of Tamoxifen resistant cells, visit our page called //Tamoxifen resistance and relation to 27HC//. When it comes to tamoxifen and ER positive breast cancer treatment, women resistant to Tamoxifen have very limited treatment options. However, with the discovery of 27HC and its promotion of ER positive breast cancer, researchers now have a new avenue to treatment for women who experience resistance. Also, due to the fact that 27HC is a much better promoter of Tamoxifen, this treatment pathway may prove much more effective and help to limit cell proliferation in the presence of Tamoxifen resistance (Nelson). It will also provide options and hope to women who may have not had a chance before the discovery of 27HC. In the future, this molecule will be the forefront of ER positive breast cancer treatment.